Copyright
©The Author(s) 2015.
World J Gastroenterol. Aug 28, 2015; 21(32): 9526-9533
Published online Aug 28, 2015. doi: 10.3748/wjg.v21.i32.9526
Published online Aug 28, 2015. doi: 10.3748/wjg.v21.i32.9526
Table 5 Main strategies of interferon-free antiviral combinations in liver transplant candidates and recipients with chronic hepatitis C virus infection
| Antiviral scheme (duration) | Antiviral activity |
| SOF + RBV (× 12 or 24 wk) | Genotype 2 or 3 (perhaps 5, 6) |
| SOF + Simeprevir ± RBV (× 12 or 24 wk) | Genotypes 1, 4 |
| SOF + Daclatasvir ± RBV (× 12 or 24 wk) | Genotypes 1, 3, 4 |
| Ledipasvir/SOF ± RBV (× 12-24 wk) | Genotypes 1, 3, 4, 6 |
| Paritaprevir/Ritonavir/Ombitasvir + Dasabuvir ± RBV (× 12 or 24 wk) | Genotype 1 |
| Paritaprevir/Ritonavir/Ombitasvir ± RBV (× 12 or 24 wk) | Genotype 4 |
- Citation: Cholongitas E, Pipili C, Papatheodoridis G. Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients. World J Gastroenterol 2015; 21(32): 9526-9533
- URL: https://www.wjgnet.com/1007-9327/full/v21/i32/9526.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i32.9526